Aili Ye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aili Ye has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Liya Gong
Department of Endocrinology, Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou 311200, China
2 shared publications - Fei Zhou
Department of Endocrinology, Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou 311200, China
1 shared publication - Jie Ni
Department of Endocrinology, Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, Zhejiang 311202, China
1 shared publication - Jieya Guo
Department of Endocrinology, Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, Zhejiang 311202, China
1 shared publication Ling Zhou
Affiliated Xiaoshan Hospital, Hangzhou Normal University/Zhejiang Xiaoshan Hospital, Hangzhou, China
1 shared publication- Quanfeng Zhu
Affiliated Xiaoshan Hospital, Hangzhou Normal University, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by XMLink in Nutrition Research and Practice
- Vol. 20 (5) , 800-819
Amelioration of chronic inflammation, insulin resistance, and gut microbiota homeostasis by a combination of Bifidobacterium , Lactobacillus , Enterococcus , and Bacillus in obese type 2 diabetic mice
Fu S, et al. Nutr Res Pract. 2026 Oct;20(5):800-819. https://doi.org/10.4162/nrp.2026.20.5.800
- 1 January 2026
- Published by XMLink in Nutrition Research and Practice
- Vol. 20 (5) , 800-819
Open AccessAmelioration of chronic inflammation, insulin resistance, and gut microbiota homeostasis by a combination of Bifidobacterium , Lactobacillus , Enterococcus , and Bacillus in obese type 2 diabetic mice
Fu S, et al. Nutr Res Pract. 2026 Oct;20(5):800-819. https://doi.org/10.4162/nrp.2026.20.5.800
- Open Access
- 8 January 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-7
Changes of CA19-9 levels and related influencing factors in patients with type 2 diabetes mellitus after antidiabetic therapy
Abnormalities of carbohydrate antigen 19 − 9 (CA19-9) are common in patients with type 2 diabetes mellitus (T2DM), and in some patients, CA19-9 returns to normal level after glycemic control. The aim of this study was to investigate the factors associated with CA19-9 levels in patients with T2DM and the associated influences on the degree of reduction of CA19-9 levels after antidiabetic therapy (AT). This study was an observational cross-sectional study. A total of 213 patients with T2DM were enrolled in this study, of whom 105 with abnormal CA19-9 and 108 with normal CA19-9. Socio-demographic information, complete blood counts, biochemical indicators, thyroid function indicators, and CA19-9 level were collected separately for each subject. Levels of glycosylated hemoglobin, type A1C (HbA1c), fasting blood glucose (FBG) were significantly higher in T2DM patients with abnormal CA19-9 compared to patients with normal CA19-9 (both FDR < 0.001). CA19-9 level was significantly and positively correlated with neutrophil/lymphocyte ratio (NLR) (r = 0.16, P = 0.02), monocyte/lymphocyte ratio (MLR) (r = 0.16, P = 0.02), and FBG (r = 0.38, P < 0.001), while significantly and negatively correlated with free triiodothyronine (FT3) (r=-0.22, P = 0.002) and albumin count (r=-0.18, P = 0.007). After AT, the degree of decrease in CA19-9 level in T2DM patients with abnormal CA19-9 was significantly positively correlated with degree of decrease in FBG (r = 0.33, P < 0.001), as well as CA19-9 level before AT (r = 0.73, P < 0.001), NLR (r = 0.20, P = 0.04), and MLR (r = 0.25, P = 0.01). In this study, we investigated the influencing factors associated with CA19-9 level and the factors influencing degree of CA19-9 reduction after AT in T2DM patients with abnormal CA19-9.
- 8 January 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-7
Open AccessChanges of CA19-9 levels and related influencing factors in patients with type 2 diabetes mellitus after antidiabetic therapy
Abnormalities of carbohydrate antigen 19 − 9 (CA19-9) are common in patients with type 2 diabetes mellitus (T2DM), and in some patients, CA19-9 returns to normal level after glycemic control. The aim of this study was to investigate the factors associated with CA19-9 levels in patients with T2DM and the associated influences on the degree of reduction of CA19-9 levels after antidiabetic therapy (AT). This study was an observational cross-sectional study. A total of 213 patients with T2DM were enrolled in this study, of whom 105 with abnormal CA19-9 and 108 with normal CA19-9. Socio-demographic information, complete blood counts, biochemical indicators, thyroid function indicators, and CA19-9 level were collected separately for each subject. Levels of glycosylated hemoglobin, type A1C (HbA1c), fasting blood glucose (FBG) were significantly higher in T2DM patients with abnormal CA19-9 compared to patients with normal CA19-9 (both FDR < 0.001). CA19-9 level was significantly and positively correlated with neutrophil/lymphocyte ratio (NLR) (r = 0.16, P = 0.02), monocyte/lymphocyte ratio (MLR) (r = 0.16, P = 0.02), and FBG (r = 0.38, P < 0.001), while significantly and negatively correlated with free triiodothyronine (FT3) (r=-0.22, P = 0.002) and albumin count (r=-0.18, P = 0.007). After AT, the degree of decrease in CA19-9 level in T2DM patients with abnormal CA19-9 was significantly positively correlated with degree of decrease in FBG (r = 0.33, P < 0.001), as well as CA19-9 level before AT (r = 0.73, P < 0.001), NLR (r = 0.20, P = 0.04), and MLR (r = 0.25, P = 0.01). In this study, we investigated the influencing factors associated with CA19-9 level and the factors influencing degree of CA19-9 reduction after AT in T2DM patients with abnormal CA19-9.
- Open Access
- 1 January 2024
- Published by XMLink in Nutrition Research and Practice
- Vol. 18 (4) , 479-497
Cryptotanshinone promotes brown fat activity by AMPK activation to inhibit obesity
Ni J, et al. Nutr Res Pract. 2024 Aug;18(4):479-497. https://doi.org/10.4162/nrp.2024.18.4.479
- 1 January 2024
- Published by XMLink in Nutrition Research and Practice
- Vol. 18 (4) , 479-497
Open AccessCryptotanshinone promotes brown fat activity by AMPK activation to inhibit obesity
Ni J, et al. Nutr Res Pract. 2024 Aug;18(4):479-497. https://doi.org/10.4162/nrp.2024.18.4.479